CSIMarket
 



Macrogenics Inc   (MGNX)
Other Ticker:  
 
 



 

What are Macrogenics Inc's Business Segments?



Macrogenics Inc is a biopharmaceutical company with a focus on discovering, developing and commercializing innovative therapeutics for the treatment of cancer and autoimmune diseases. The company offers a range of products and services, which can be broadly classified into three segments: Clinical Programs, Technology Platforms, and Intellectual Property.

Clinical Programs:
Macrogenics Inc has a strong and diversified clinical pipeline, with multiple product candidates in various clinical stages of development. The companyes lead product candidate is Margetuximab, a monoclonal antibody for the treatment of HER2-positive breast cancer. The company has also developed other monoclonal antibodies, such as Flotetuzumab, MGA271, and MGD013, that are being investigated to treat different types of cancer, including hematological malignancies and solid tumors. Additionally, the company is developing advanced bi-specific antibodies, such as DuoBody-CD3xCD20 and DuoBody-PD-L1x4-1BB, which have the potential to address unmet medical needs in oncology.

Technology Platforms:
Macrogenics Inc has developed several proprietary technology platforms that enable the discovery and development of innovative therapeutic candidates. These platforms include DART (Dual-Affinity Re-Targeting), Fc Optimization, and XmAb. DART technology enables the creation of bispecific antibodies that can bind to two different targets simultaneously. Fc Optimization involves modifying the Fc region of antibodies to enhance their potency, durability, and safety profile. XmAb technology is a modular platform that allows the creation of antibodies with specific functions and properties, such as improved tumor targeting, effector function, or half-life.

Intellectual Property:
Macrogenics Inc has an extensive intellectual property portfolio, consisting of patents, trademarks, and trade secrets. The companyes patents cover its proprietary technology platforms, as well as its product candidates and their methods of use. Additionally, Macrogenics Inc has licensed certain technologies from other companies that complement its own technology platforms.

In summary, Macrogenics Inc offers an innovative and diverse portfolio of clinical programs, technology platforms, and intellectual property that collectively enable the discovery, development, and commercialization of new therapeutics for cancer and autoimmune diseases.
   

Macrogenics Inc Tax Rate Companies within the Major Pharmaceutical Preparations Industry


Business Segments Q4
Revenues
(in millions $)
Q4
Income
(in millions $)
(Dec 31 2023)
%
(Profit Margin)
Total 10.72 -46.07 -

Growth rates by Segment Q4
Y/Y Revenue
%
(Dec 31 2023)
Q/Q Revenue
%
Q4
Y/Y Income
%
(Dec 31 2023)
Q/Q Income
%
Total -85.33 % 3.11 % - -

To get more information on Macrogenics Inc's Total segment. Select each division with the arrow.


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com